Gene Logic Drug Candidate Shows Positive In Vivo Test Results
July 27 2007 - 8:45AM
Business Wire
Gene Logic Inc. (NASDAQ: GLGC) announced today that GL1001, the
company�s clinical-stage drug candidate, showed indications of
efficacy at relevant doses in in vivo testing for inflammatory
bowel disease (IBD). Based on the in vivo test results and market
opportunities in IBD, the Company is seeking a partner for the
clinical development of GL1001. Gene Logic discovered the new
potential therapeutic use for GL1001 using its Drug Repositioning
Platform, a diverse set of drug evaluation technologies the Company
uses to assess drug candidates for potential utility across a wide
spectrum of disease indications. GL1001 was found to suppress the
induction of a key inflammatory mediator both in vivo and in vitro.
The data were also supported by analysis of Gene Logic�s
proprietary gene expression database, BioExpress�. Gene Logic
performed the work under an agreement with Millennium
Pharmaceuticals and subsequently acquired certain exclusive rights
to GL1001 for commercial development. IBD is a chronic health
problem characterized by inflammation and swelling in the digestive
tract, leading to ulcers and bleeding. Symptoms may include
cramping, abdominal pain, and diarrhea. There are two main types of
inflammatory bowel disease: ulcerative colitis and Crohn�s disease,
and the conditions affect as many as 1 million Americans. Gene
Logic�s Drug Repositioning Program seeks to find alternative
development paths for drug candidates with good safety records that
have been de-prioritized or discontinued in clinical trials. The
program offers pharmaceutical partners a novel approach to bolster
their pipelines with high-quality drug candidates that originated
from their own R&D efforts. The program can also yield
proprietary drug candidates for the Company when a partner chooses
not to develop a compound for a use identified by the Company.
Charles L. Dimmler, III, Gene Logic CEO and President, commented,
�Our in vivo tests provide data that indicate GL1001 has the
potential to treat IBD. We also view this in vivo proof-of-concept
as further evidence that our Drug Repositioning Platform has the
potential to yield clinically interesting drug development
opportunities that may be validated in industry-standard models of
efficacy. Our next step will be to secure the right partner to
pursue a clinical development strategy for GL1001. At the same
time, we are working with our existing drug repositioning partners
to discover new uses for their discontinued drug candidates in
other therapeutic areas.� Gene Logic Overview Gene Logic is
transforming into a pharmaceutical development company through
partnerships with pharmaceutical companies. Our partners provide
Gene Logic with access to their drug candidates that have been
assessed as safe in human clinical trials but discontinued for
other reasons. Gene Logic applies its drug indication platform to
find new therapeutic uses for the drug candidates. Gene Logic
expects to receive milestone payments and royalties on drug
candidates that our partners choose to develop based on the
indications we find or, if the partner elects not to pursue such
new indications, Gene Logic may receive ownership and development
rights. Gene Logic has also developed proprietary genomics
databases and services to enable customers worldwide to discover
and prioritize drug targets, identify biomarkers, predict toxicity
and understand mechanisms of toxicity, and obtain insights into the
efficacy of specific compounds. We continue to offer customers
these services and licenses to the databases. Such databases,
services and expertise are also a vital part of our drug indication
platform. Following consideration of various strategic alternatives
for its Genomics Division, the Company is concentrating its efforts
on investigating the possibility of a sale of all or parts of its
Genomics business while continuing to serve new and existing
Genomics customers. Founded in 1994, Gene Logic is headquartered in
Gaithersburg, Md., with additional research and development
facilities in Cambridge, Mass. The Company currently has about 150
employees worldwide. For more information, visit www.genelogic.com
or call toll-free � 1/800/GENELOGIC.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Aug 2023 to Aug 2024